whatshot

SNY   $48.27  -0.02% Market Open

Sanofi SA
show_chart Advanced Chart of SNY
Last Events:

2023-10-27 The hottest instrument.

2023-08-09 Trend pattern changed from восходящий треугольник to канал.

2023-08-09 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Signal in MACD changed from bearish reversal to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-08-05 Trend changed from linear up to up and flat.

2023-08-04 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-04 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

Current temperature: 11.46
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 48.89
High with % probability:
Analyst Recommendations:
Number of estimates 4
Target Price Mean 62.11
Mean unverified/preliminary 62.11 / 62.11
Target Price Low / High 56.00 / 67.00
Median / STD DEV 62.72 / 5.49
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi ActivelyBuy Sell Sell
macd None None None
stoch None None None
ma20 ActivelyBuy ActivelyBuy ActivelyBuy
ma50 None None None
ma100 Sell Sell None
Candlestick PatternNov. 19, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US80105N1054
ceo Mr. Paul Hudson
Website https://www.sanofi.com
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.